[G23-13] Olaparib (prostate cancer) – Second Addendum to Commission A23-03
Last updated 06.07.2023
Project no.:
G23-13
Commission:
Commission awarded on 23.05.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Application field:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
| Project no. | Title | Status |
|---|---|---|
| A23-03 | Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V | Commission completed |
Federal Joint Committee (G-BA)
2023-07-06 A G-BA decision was published.